Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway
Cell Biology and Toxicology,
Год журнала:
2025,
Номер
41(1)
Опубликована: Янв. 29, 2025
Esketamine,
a
newly
developed
antidepressant,
is
the
subject
of
this
research
which
seeks
to
explore
its
impact
on
depressive
symptoms
in
neuropathic
pain
mice
and
potential
molecular
mechanisms
involved.
Through
transcriptome
sequencing
bioinformatics
analysis
combined
with
vivo
studies,
it
was
identified
that
esketamine
markedly
boosts
levels
m6A
methyltransferase
METTL3
AMPA
receptor
GluA1
subunit.
Esketamine
activates
METTL3,
allowing
bind
mRNA,
promoting
modification,
thereby
enhancing
expression
at
synapses.
mechanism,
may
reduce
depressive-like
behavior
mice,
providing
new
insights
into
applications
novel
therapeutic
avenues
for
behavior.
Язык: Английский
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression
JAMA Psychiatry,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 2, 2025
Treatment-resistant
depression
(TRD)
remains
a
critical
challenge
in
psychiatry,
with
limited
effective
options.
Esketamine,
rapid-acting
antidepressant,
is
usually
combined
selective
serotonin
reuptake
inhibitor
(SSRI)
or
serotonin-norepinephrine
(SNRI),
but
comparative
evidence
of
these
combinations'
effectiveness
real-world
settings
sparse.
To
determine
whether
the
combination
esketamine
+
SNRI
shows
differences
clinical
outcomes
compared
to
SSRI
patients
TRD.
This
retrospective
cohort
study
was
conducted
September
2024
using
data
from
TriNetX
global
health
research
network,
5-year
time
window
first
trial.
are
drawn
and
use
electronic
medical
records
more
than
90
care
centers
across
20
countries.
Adults
TRD
who
were
treated
either
an
eligible
for
inclusion.
Treatment
(citalopram,
escitalopram,
fluoxetine,
fluvoxamine,
paroxetine,
sertraline,
vilazodone)
(desvenlafaxine,
duloxetine,
levomilnacipran,
milnacipran,
venlafaxine).
The
primary
all-cause
mortality,
hospitalization,
relapse,
suicide
attempts.
Kaplan-Meier
survival
analysis
used
estimate
probabilities,
while
risk
ratios
odds
calculated
all
outcomes.
In
population-based
sample
61
882
adult
participants
SNRI,
55
480
selected
after
applying
propensity
score
matching
age
sex.
These
divided
into
2
matched
cohorts:
27
740
(16
007
female
[57.7%];
mean
[SD]
age,
46.0
[21.3]
years)
242
[58.6%];
45.9
[21.9]
years).
entire
population,
incidence
hospitalizations,
depressive
relapses,
attempts
low
throughout
period.
Patients
group
had
significantly
lower
mortality
(5.3%
vs
9.1%;
P
<
.001),
hospitalization
rates
(0.1%
0.2%;
relapses
(14.8%
21.2%;
.001)
group,
which
instead
showed
suicidal
(0.3%
0.5%;
=
.04).
this
study,
among
sample,
low.
slightly
Язык: Английский
Effect of ketamine enantiomers and maternal deprivation on depressive-like behavior and plasma concentration of BDNF in rats
Research Society and Development,
Год журнала:
2024,
Номер
13(7), С. e8313746352 - e8313746352
Опубликована: Июль 15, 2024
Background:
Low
doses
of
different
ketamine
enantiomers
have
demonstrated
rapid
behavioural
and
biological
actions
in
animals
with
depressive-like
behavior.
However,
some
authors
report
effects
depending
on
model
depression
isomer
used.
Objective:
Our
primary
aim
was
to
evaluate
the
effect
behavior,
anhedonic-like
behavior
locomotor
activity
rats
subjected
maternal
deprivation
(MD).
Secondarily,
we
investigated
Brain-derived
neurotrophic
factor
plasma
concentration
between
experimental
groups.
Methods:
Male
(n=71)
were
randomized
into
seven
groups:
one
non-deprived
placebo
other
six
deprived
split
control
intervention
Rats
treated
a
single
intraperitoneal
dose
ketamine,
esketamine,
or
arketamine.
One
hour
after
drug
application,
performed
tests
antidepressant-like
activity.
Furthermore,
blood
collected
measure
plasmatic
BDNF
levels.
Results:
We
did
not
observe
induction
MD.
there
no
change
(F
(6,64)
=
0.9664,
p=0.455)
all
Conclusion:
Neither
MD
nor
isomers
able
Язык: Английский